- Home
- INMB vs TVRD Comparison
INMB vs TVRD Comparison
Compare INMB & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INMB | TVRD |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.3M | 36.8M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | INMB | TVRD |
|---|---|---|
| Price | $1.13 | $3.18 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 7 |
| Target Price | $5.40 | ★ $51.67 |
| AVG Volume (30 Days) | ★ 427.8K | 38.4K |
| Earning Date | 03-30-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11.85 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $50,000.00 | N/A |
| Revenue This Year | $264.29 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 257.14 | N/A |
| 52 Week Low | $1.10 | $3.05 |
| 52 Week High | $11.64 | $43.65 |
Technical Indicators
Market Signals| Indicator | INMB | TVRD |
|---|---|---|
| Relative Strength Index (RSI) | 37.50 | 33.33 |
| Support Level | N/A | N/A |
| Resistance Level | $1.48 | $4.52 |
| Average True Range (ATR) | 0.08 | 0.27 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 10.61 | 7.58 |
Price Performance
Historical ComparisonAbout INMB INmune Bio Inc.
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.
About TVRD Tvardi Therapeutics Inc.
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.